Frontlight ResearchEarly access
CompletedPhase 4
Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Birmingham, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 33 people enrolled
- Started
- 1 Sept 2020
- Ended
- 22 Jan 2026
- Type of study
- Interventional
- Treatments tested
- Flumist Quadrivalent Nasal Product
- Record updated
- 25 September 2026
Who can take part
- Age
- 18 years to 49 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- ages 18-49 years old,
- not yet received influenza vaccine for 2019-2020, and
- capable of giving signed informed consent
Who cannot take part
- prior adverse reaction to influenza vaccine,
- Immunocompromising condition (e.g. HIV/AIDS, chemotherapy, immune suppressing medications),
- asthma, chronic lung/liver/kidney /neurologic/hematologic/metabolic disorders,cardiovascular disease (excluding isolated hypertension), diabetes mellitus, disease, congestive heart failure,
- current or recent (within the past month) upper/lower respiratory tract infection, chronic sinusitis/nasal allergies requiring frequent or daily therapy (including topical corticosteroids),
- history of Guillain-Barre syndrome,
- egg allergy,
- active smoking within past 6 months,
- pregnancy,
- close contact with an individual with severe immunodeficiency/immunosuppression
Where in United States
- UAB Lung Health CenterBirmingham, United States
About the trial
What the trial wants to find out
The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)
The group in the trial
- open labelOther group
FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
Treatment: Flumist Quadrivalent Nasal Product
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Endoplasmic Reticulum Stress Disrupts the Airway Epithelium and Reduces Host Defense during Influenza A Virus Infection.American journal of respiratory cell and molecular biology, 2026
- Record updated
- 25 September 2026